AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2019
Jun 5, 2019
32312_dirs_2019-06-05_2e52f849-122d-4e9d-9ba3-dd4b2b986b69.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-06-03
Reporting Person: Tomasello Shawn (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-06-03 | Stock Option (Right to Buy) | $34.83 | A | 10000 | Acquired | 2029-06-02 | Ordinary Shares (10000) | Direct |
Footnotes
F1: The shares underlying the stock option will vest in equal quarterly installments over a period of two years.
More from UroGen Pharma Ltd.
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 4